Sanctuary Advisors LLC Invests $312,000 in Grifols, S.A. (NASDAQ:GRFS)

Sanctuary Advisors LLC bought a new stake in Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 35,886 shares of the biotechnology company’s stock, valued at approximately $312,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in shares of Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares during the period. NBC Securities Inc. raised its holdings in Grifols by 2.8% during the third quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 1,433 shares in the last quarter. HighTower Advisors LLC raised its stake in Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,546 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the last quarter. Finally, US Bancorp DE lifted its stake in Grifols by 12.3% in the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 2,256 shares during the last quarter.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Price Performance

Grifols stock opened at $7.65 on Friday. The company has a market cap of $5.26 billion, a P/E ratio of 7.89 and a beta of 0.43. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15. The business has a fifty day moving average of $8.27 and a two-hundred day moving average of $8.12. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.